JPL Wealth Management LLC Acquires Shares of 11,204 Pfizer Inc. (NYSE:PFE)

JPL Wealth Management LLC bought a new stake in Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 11,204 shares of the biopharmaceutical company’s stock, valued at approximately $297,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PFE. Impact Capital Partners LLC bought a new position in shares of Pfizer during the 4th quarter valued at about $287,000. CFO4Life Group LLC increased its holdings in shares of Pfizer by 2.2% during the 4th quarter. CFO4Life Group LLC now owns 28,725 shares of the biopharmaceutical company’s stock worth $762,000 after acquiring an additional 614 shares during the last quarter. Balboa Wealth Partners increased its holdings in shares of Pfizer by 1.6% during the 4th quarter. Balboa Wealth Partners now owns 30,678 shares of the biopharmaceutical company’s stock worth $814,000 after acquiring an additional 480 shares during the last quarter. Achmea Investment Management B.V. acquired a new position in Pfizer in the 4th quarter valued at $2,812,000. Finally, Rakuten Securities Inc. grew its holdings in Pfizer by 10.2% in the 4th quarter. Rakuten Securities Inc. now owns 29,424 shares of the biopharmaceutical company’s stock valued at $781,000 after buying an additional 2,734 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Pfizer Trading Down 1.0 %

PFE stock opened at $25.73 on Thursday. The company’s 50-day simple moving average is $26.28 and its 200-day simple moving average is $27.18. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The firm has a market cap of $145.79 billion, a P/E ratio of 18.24, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s revenue was up 24.7% on a year-over-year basis. During the same period last year, the company posted $0.10 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on PFE shares. UBS Group cut their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Wolfe Research assumed coverage on Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target for the company. Truist Financial decreased their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Bank of America reaffirmed a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.